

and kinetic binding studies yielded a rank order of potency for CYSLTR1 of zafirlukast = montelukast > pranlukast (15).

Studies have indicated that polymorphisms in genes encoding proteins of the leukotriene synthetic pathway contribute to intra-patient variations in clinical responses to CYSLTR1 antagonists. CYSLTs are synthesized through the 5-lipoxygenase (5-LO, *ALOX5*) pathway of arachidonic acid metabolism. *ALOX5* is the first committed enzyme in the biosynthetic pathway leading to production of the leukotrienes (16). *ALOX5* gene promoter polymorphism has been shown to be associated with altered responses to treatment with antileukotriene drugs (17, 18) and airway hyper-responsiveness to methacholine (19). Another member of the pathway, LTC4 synthase (LTC4S), is a terminal enzyme that catalyzes the conjugation of unstable LTA4 with reduced glutathione to form LTC4. The -444A/C polymorphism in *LTC4S* is predictive of the clinical response to pranlukast in a Japanese population (20).

These findings suggest that *CYSLTR1* may be a good candidate gene for asthma and allergic rhinitis. A recent screen of the NCBI database (<http://www.ncbi.nlm.nih.gov>) revealed that *CYSLTR1* contains three exons, but the genomic structure and regulatory region of *CYSLTR1* have not been fully characterized. To date, there has been only one study to examine possible associations of allergic diseases with *CYSLTR1* polymorphisms. 927C/T polymorphism in *CYSLTR1* was examined with asthma in 585 Japanese asthmatic patients and 323 controls, but no association was observed (21). In the present study, we characterized the genomic structure of human *CYSLTR1* and performed association studies of asthma/allergic rhinitis with *CYSLTR1* polymorphisms in a Japanese population.

## Methods

### Subjects

Probands of asthmatic families were mite-sensitive asthmatic children who visited the Pediatric Allergy Clinic of the University Hospital of Tsukuba. A full verbal and written explanation of the study was given to all family members interviewed, and 137 families (466 members), including 45 families used for our previous genome-wide screening (22), gave informed consent and participated in this study. Criteria used for the diagnosis of asthma were as described previously (22).

Probands of the allergic rhinitis families were children with allergic rhinitis who were recruited from three elementary schools and a junior high school in Matsukawa, a farming community in central Japan where orchard grass pollens are thought to be a major cause of seasonal allergic rhinitis. Children with allergic rhinitis were identified through a questionnaire, and diagnosis was made by physicians. Other family members were contacted, and a total of 48 families (188 individuals) who gave informed consent participated in this study. Criteria used for the diagnosis of seasonal allergic rhinitis were as described previously (23). This study was approved by the Committee of Ethics of the University of Tsukuba.

### Mutation screening and genotyping

All exons and exon-intron junctions and the 5' flanking region of *CYSLTR1* were amplified by polymerase chain reaction (PCR) from genomic DNAs of 24 unrelated Japanese females with seasonal allergic rhinitis. Genotyping was carried out with the Big Dye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Foster City, CA, USA) on an ABI 3100 autosampler (Applied Biosystems).

### 5' rapid amplification of cDNA end

We carried out 5' rapid amplification of cDNA end (5' RACE) experiments using commercially available RACE-ready human leukocyte and spleen cDNAs (Marathon Ready cDNA; BD Biosciences/Clontech, Palo Alto, CA, USA) according to the manufacturer's instructions. Primers used for the amplification were: 5'-GCCATTGCCAAAGAAGCCTACAACAG-3' and 5'-CCATCCTAATACGACTCACTATAGGGC-3'(AP1) for the first round PCR, and 5'-TGCCTCTTTCTGGCACTGGAGTACCTT-3' and 5'-ACTCACTATAGGGCTCGAGCGGC-3' (AP2) for the nested PCR. The amplified RACE product was cloned in pCR2.1 TOPO-TA cloning vector (Invitrogen, San Diego, CA, USA). Each white (positive) clone was isolated and grown in Luria-Bertani medium with ampicillin overnight. Plasmids were purified by column chromatography (Invisorb Spin Plasmid Mini Kit; Invitex GmbH, Berlin, Germany) and subjected to direct sequencing with M13 primers.

### Expression of *CYSLTR1* in tissues

Human multiple tissue, human immune system, and human blood fraction cDNA panels

Table 1. Sequence of primers used in reverse transcriptase-polymerase chain (RT-PCR) reaction and plasmid constructs

RT-PCR	
Primer pair I-III	
Forward	5'-AGAGAACACTCGTCCCTGCT-3'
Reverse	5'-CTTGATTGCGGAAGTCATCA-3'
Primer pair II-III	
Forward	5'-AGCGTGGGCTTCCTCTAATA-3'
Reverse	5'-CTTGATTGCGGAAGTCATCA-3'
Plasmid constructs	
24 bp	
Forward	5'-ATTATAAGCTTAAGCAGGGACGAGTGTCTCTCT-3'
Reverse	5'-ATTATAGATCTAAGAGAGAACACTCGTCCCTGCTT-3'
-30 bp	
Forward	5'-ATTATAAGCTTAAGCAGGGACGAGTGTCTCTCT CAGCTTAGTCTC-3'
Reverse	5'-ATTATAGATCTCTCACAGTACAGAAATCACAGAG AACTAAGCTGAAG-3'
-108 bp	
Forward	5'-ATTATAAGCTTAAGCAGGGACGAGTGTCTCT-3'
Reverse	5'-AATTATAGATCTCAAGTTTCACATAATGCCAGTT-3'
-345 bp	
Reverse	5'-AATTATAGATCTTCCAACACAGGACCATGA-3'
-665 bp	
Reverse	5'-AATTATAGATCTGGCTACTGCTGGGCTCATATT-3'
-1253 bp	
Reverse	5'-AATTATAGATCTGTGTGCTGGGGTATGGTA-3'
-1604 bp	
Reverse	5'-AATTATAGATCTAGGGAGGTAGCAGAGCAA-3'

The forward primer for the constructs of -345 bp, -665 bp, -1253 bp and -1604 bp is the same as that of -108 bp.

(Clontech) were used to analyze expression of *CYSLTR1* in various tissues. PCR primers are listed in Table 1. Resting CD14<sup>+</sup> (monocytes), CD4<sup>+</sup> (T helper/inducer cells), CD8<sup>+</sup> (T suppressor/cytotoxic cells) and CD19<sup>+</sup> (B lymphocytes) cells were positively selected from mononuclear cells produced by healthy donors by immunomagnetic separation with Dynabeads M-450 (Dyna, Oslo, Norway). Cells were activated with pokeweed mitogen (PWM; Invitrogen) and concanavalin A (ConA; ICN, Costa Mesa, CA, USA) by standard methods, and the degree of activation of lymphocytes was estimated on the basis of morphological criteria (blast morphology and mitoses) and expression of two activation markers, CD25 (interleukin-2 receptor) and CD71 (transferrin receptor). We used glycerol-3-phosphate dehydrogenase (G3PDH) as an internal control for PCR. Amplification conditions were an initial denaturation step at 94°C for 10 min followed by 40, 34 and 30 cycles of denaturation at 94°C for 30 s, annealing at 60°C for 30 s and extension at 72°C for 30 s for primer pairs I-III, II-III and G3PDH, respectively.

#### RNA preparation and reverse transcriptase-PCR analysis

Lymphocytes from peripheral blood were isolated by Ficoll-Paque gradient centrifugation

(Amersham Biosciences, Piscataway, NJ, USA). Total RNA was isolated from lymphocytes with RNeasy® MiNi Kit (Qiagen, San Diego, MD, USA) and cDNA was prepared with Taqman reverse transcription (RT) reagents (Applied Biosystems) at 25°C for 10 min, 48°C for 30 min, and 95°C for 5 min. Amplification condition consisted of an initial denaturing step of 95°C for 10 min, followed by 38 cycles of 94°C for 30 s, 60°C for 30 s, 72°C for 30 s, with a final incubation at 72°C for 3 min. PCR products were separated by electrophoresis on 15% polyacrylamide gel at 4°C overnight. Bands were excised from the gels and purified with QIA® II Gel Extraction Kit (Qiagen). PCR products were then cloned in pCR2.1 TOPO-TA cloning vector (Invitrogen). Direct sequencing was carried out with the Big Dye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems) on an ABI 3100 autosequencer (Applied Biosystems).

#### Plasmid construction and transfection, and luciferase assay

Genomic fragments of the 5' flanking region of exon 1 of *CYSLTR1* were amplified with the primers listed in Table 1. PCR products were digested with *Bgl*II and *Hind*III overnight at 37°C and then subcloned in pGL3-Basic vector (Promega, Madison, WI, USA) digested with *Bgl*II and *Hind*III. U937 cells (Cell Resource Center for Biomedical Research, Tohoku University, Miyagi, Japan) were resuspended in RPMI 1640 (Sigma-Aldrich Co., St Louis, MO, USA) supplemented with 10% fetal calf serum (Sigma-Aldrich). Approximately  $1 \times 10^7$  cells were cotransfected with 30 µg of test construct and 150 ng of pRL-TK (Promega) by electroporation with a Gene Pulsar II (Bio-Rad, Hercules, CA, USA) set at 350 V and 950 µF for U937. Transfected cells were harvested 5 h after transfection. Cells were lysed by the addition of 200 µl of lysis buffer (Promega). A volume of 20 µl of each lysate was used for the luciferase assay with the Dual-Luciferase Reporter Assay System (Promega). The firefly luciferase values were normalized to the Renilla luciferase values of pRL-TK, which were determined at the same time. Reporter activity is presented as the mean of at least three independent measurements.

#### Statistical analysis

Transmission disequilibrium test (TDT)-chromosome X was analyzed with the UNPHASED package (<http://www.litbio.org/access.htm>) (24). Differences in transcriptional activity in reporter assays were analyzed with the Wilcoxon test.

**Results**

Isolation of 5' full-length *CYSLTR1* transcripts and structure of the human *CYSLTR1* gene

Current information in the NCBI database (<http://www.ncbi.nlm.nih.gov>) indicates that *CYSLTR1* is composed of three exons and two introns, and the cDNA is 1537 bp long (NM\_006639). Our present 5' RACE experiments with cDNAs derived from human leukocytes and spleen were successful and added an additional 225 bp of sequence to the 5' side of the available sequence (Fig. 1a, b). No additional novel exons were detected.

Tissue expression of *CYSLTR1*

Splice variants of *CYSLTR1* were examined with cDNA derived from lymphocytes. Five splice variants were detected, and the structure of each variant is shown in Fig. 2. Variants A and C were the dominant transcripts in lymphocytes. Variant

A was the longest transcript, whereas variant C lacked a part of exon 1. Variant B lacked all of exon 2, and both variant D and variant E lacked a part of exon 1 and all of exon 2. Expression of *CYSLTR1* in various human tissues was analyzed with a PCR-based method (Fig. 3a-c). We designed primers to amplify the regions between exons 1 and 3 (expected product size 691 bp, primer pair I-III) and between exons 2 and 3 (expected product size 189 bp, primer pair II-III) (Fig. 1a). Transcripts including exons 2 and 3 were observed in most tissues analyzed. We observed multiple splice variants in the transcripts including exons 1, 2 and 3. Variant A was the major product in lung, and several splice variants were observed in brain, placenta, liver, kidney and pancreas (Fig. 3a). Variants A and C were observed in tonsil, leukocytes, spleen and lymph node. Variant C was expressed weakly in thymus and bone marrow (Fig. 3b). Variant A was present in resting CD4+, CD14+, CD8+ and CD19+ cells, and in activated CD4+ cells




Fig. 1. Genomic structure and cDNA sequence of human cysteinyl leukotriene receptor 1 (*CYSLTR1*). (a) Top, genomic structure of human *CYSLTR1* gene. Boxes mark the positions of exons 1-3. The open box is the region we extended in our 5' rapid amplification of cDNA end (5' RACE) experiment. *CYSLTR1* contains three exons, and the coding sequence (CDS) starts with exon 3. Arrows indicate the locations of the polymorphisms. The positions of primer pairs I-III and II-III are shown. Bottom, genomic sequences of exon-intron junctions in *CYSLTR1*. (b) Sequence of the human *CYSLTR1* cDNA. Numbers are relative to the translation initiation site. Boundaries between exons are indicated by arrows. The 5' RACE extended sequence is italicized. Splice sites for variants C and D are indicated with closed triangles, and the splice site for variant E is shown with an open triangle.




Fig. 2. Splice variants of cysteinyl leukotriene receptor 1 (*CYSLTR1*). There are five *CYSLTR1* variants in lymphocytes (a) and the structure of each variant is shown in (b). The size in bp of each exon is indicated in the box. CDS and arrows indicate the start site of the coding sequence.

and monocytes, but was not expressed in activated CD8<sup>+</sup> cells (Fig. 3c). We could not find a human sequence corresponding to band X, which was observed in kidney, fetal liver, tonsil and leukocytes (Fig. 3a, b), by BLAST search with human genome sequence database (<http://www.ncbi.nlm.nih.gov/BLAST/>), therefore, we considered band X as PCR artifact.

Polymorphism search and TDT analysis

We screened for polymorphisms in DNAs from 32 unrelated female subjects and found four polymorphisms c.-618-334T/C (rs321029), c.-618-275C/A (rs2637204), c.-618-136G/A (rs2806489) and 927C/T (rs20995), in *CYSLTR1* (Fig. 1a). We numbered these according to the recommendation of nomenclature system published previously (25). These four polymorphisms are in




Fig. 3. Expression of cysteinyl leukotriene receptor 1 (*CYSLTR1*) in human multiple tissue panels. Results of polymerase chain reaction amplification of body organs (a), immune system (b), and blood fractions (c) are shown. Glycerol-3-phosphate dehydrogenase is included as an internal control. Mono, monocytes; r, resting; a, activated; NC, no-template control. Four bands (A, B, X and C) were observed, and the splice structures of bands A, B and C are depicted in Fig. 2b.

complete linkage disequilibrium with each other ( $r^2 = 1$ ). We performed TDT analysis of chromosome X, and none of the polymorphisms was associated with asthma or allergic rhinitis (CAAT haplotype: transmitted 26, not transmitted 26,  $p = 1.0$  for asthma; and transmitted 12, not transmitted 10,  $p = 0.67$  for rhinitis). The frequency of CAAT haplotype in parents was 56% and that of the TCGC haplotype was 44%.

Transcriptional activities of 5' flanking region of *CYSLTR1*

To examine the transcriptional activity in the 5' flanking region of *CYSLTR1*, we constructed plasmids that contained sequences from -1604, -1235, -665, -345, -108, and -30 to +24 relative to the transcription initiation site. The primers used for plasmid construction are listed in Table 1. The expression of *CYSLTR1* in U937 cells was confirmed by RT-PCR (data not shown). These constructs were then transiently transfected into U937 cells. Deletion analysis revealed that the region driving maximal reporter

gene expression in U937 cells was located -665 bp proximal to the transcription initiation site (Fig. 4). Two larger constructs, one from -1604 and the other from -1235, have lower luciferase activities than construct -665, suggesting that negative regulatory sites may be present in this region.

To determine whether the c.-618-434T/C, c.-618-275C/A, and c.-618-136G/A polymorphisms are functional, we generated luciferase reporter gene constructs that contained the 5' flanking region of *CYSLTR1* from exon 1 to -665 bp, and differed from wildtype only with c.-618-434C, c.-618-275A, and c.-618-136A. The three polymorphisms in the promoter (c.-618-434T/C, c.-618-275C/A, and c.-618-136G/A) and 927C/T are in complete linkage disequilibrium ( $r^2 = 1$ ) with each other, so only two promoter haplotypes (TCG and CAA) exist in the population. The construct containing the TCG haplotype had higher transcriptional activity than that containing the CAA haplotype ( $p = 0.049$ ), suggesting that the TCG and CAA haplotypes have different transcriptional activities and may contribute to altered expression of *CYSLTR1* (Fig. 5).




Fig. 4. Reporter activity in U937 cells. Each construct was transfected into U937 cell as described in *Methods*. Luciferase activity is presented relative to Renilla activity, and all values are the mean  $\pm$  s.d. of at least three independent experiments.




Fig. 5. Effect of the three polymorphisms on cysteinyl leukotriene receptor 1 (*CYSLTR1*) promoter activity. Luciferase activity is presented relative to Renilla activity, and values are the mean  $\pm$  s.d. of at least three independent experiments.

## Discussion

In the present study, we investigated the genomic structure and transcriptional activity of *CYSLTR1* and examined possible associations of *CYSLTR1* polymorphisms with asthma/rhinitis. We isolated the full-length genomic region of *CYSLTR1* and characterized the promoter region of *CYSLTR1*. We found four polymorphisms in *CYSLTR1*, but none was associated with asthma or allergic rhinitis by TDT.

Our 5' RACE analysis revealed that *CYSLTR1* contains three exons and extended the previous sequence data by 225 bp on the 5' side. Exons 1 and 2 are non-coding, and the entire open reading frame is located in exon 3. We found that there are five different *CYSLTR1* transcripts in lymphocytes. These transcripts do not change the putative open reading frame; all variants are predicted to encode identical proteins. However, it is possible that the differences in the transcripts influence the stability or secondary structure of the mRNA, which alters translation of the transcript to protein.

Genome-wide analyses of alternative splicing indicate that 40–60% of human genes have alternative splice forms, suggesting that alternative splicing is one of the most significant components of the functional complexity of the human genome (26). Recent studies showed that a majority of alternative splices change the protein product (26, 27). However, in the present study, the alternative splicing sites in the variants occurred outside of the coding region. This suggests that a strict conformation of the *CYSLTR1* protein is essential for its function in leukotriene signaling.

Tissue distribution of *CYSLTR1* has been examined extensively. Northern blot analysis revealed the highest level of expression in peripheral blood leukocytes, followed by spleen, lung, pancreas, small intestine and other tissues (10, 11). RT-PCR and *in situ* hybridization showed expression in eosinophils, neutrophils, B cells, T cells, mast cells, and CD14+, CD19+ and CD34+ cells (12, 28, 29). In the present study, we examined expression of the different transcripts in many tissues. Transcripts including exons 2 and 3 were observed in most tissues tested. However, expression of transcripts originating from exon 1 varied significantly in different tissues. Our data suggest that transcripts originating from exon 2 are the dominant transcripts in some tissues, such as thymus and bone marrow. Interestingly, transcripts from exon 1 were observed in resting CD8+ cells but not in activated CD8+ cells, suggesting that expression



- human lung parenchyma. *Biochem Pharmacol* 2002; 63: 1537–46.
16. SAMUELSSON B, DAHLEN SE, LINDGREN JA, ROUZER CA, SERHAN CN. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. *Science* 1987; 237: 1171–6.
  17. IN KH, ASANO K, BEIER D, et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. *J Clin Invest* 1997; 99: 1130–7.
  18. DRAZEN JM, ISRAEL E, O'BYRNE PM. Treatment of asthma with drugs modifying the leukotriene pathway. *N Engl J Med* 1999; 340: 197–206.
  19. KIM SH, BAE JS, SUH CH, NAHM DH, HOLLOWAY JW, PARK HS. Polymorphism of tandem repeat in promoter of 5-lipoxygenase in ASA-intolerant asthma: a positive association with airway hyperresponsiveness. *Allergy* 2005; 60: 760–5.
  20. ASANO K, SHIOMI T, HASEGAWA N, et al. Leukotriene C4 synthase gene A(–444)C polymorphism and clinical response to a CYS-LT(1) antagonist, pranlukast, in Japanese patients with moderate asthma. *Pharmacogenetics* 2002; 12: 565–70.
  21. UNOKI M, FURUTA S, ONOUCHI Y, et al. Association studies of 33 single nucleotide polymorphisms (SNPs) in 29 candidate genes for bronchial asthma: positive association a T924C polymorphism in the thromboxane A2 receptor gene. *Hum Genet* 2000; 106: 440–6.
  22. YOKOUCHI Y, NUKAGA Y, SHIBASAKI M, et al. Significant evidence for linkage of mite-sensitive childhood asthma to chromosome 5q31-q33 near the interleukin 12 B locus by a genome-wide search in Japanese families. *Genomics* 2000; 66: 152–60.
  23. YOKOUCHI Y, SHIBASAKI M, NOGUCHI E, et al. A genome-wide linkage analysis of orchard grass-sensitive childhood seasonal allergic rhinitis in Japanese families. *Genes Immun* 2002; 3: 9–13.
  24. DUDBRIDGE F, KOELEMAN BP, TODD JA, CLAYTON DG. Unbiased application of the transmission/disequilibrium test to multilocus haplotypes. *Am J Hum Genet* 2000; 66: 2009–12. E-pub Apr 13.
  25. ANTONARAKIS SE. Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group. *Hum Mutat* 1998; 11: 1–3.
  26. MODREK B, LEE C. A genomic view of alternative splicing. *Nat Genet* 2002; 30: 13–9.
  27. KAN Z, ROUCHKA EC, GISH WR, STATES DJ. Gene structure prediction and alternative splicing analysis using genomically aligned ESTs. *Genome Res* 2001; 11: 889–900.
  28. MELLOR EA, MAEKAWA A, AUSTEN KF, BOYCE JA. Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells. *Proc Natl Acad Sci U S A* 2001; 98: 7964–9.
  29. MITA H, HASEGAWA M, SAITO H, AKIYAMA K. Levels of cysteinyl leukotriene receptor mRNA in human peripheral leucocytes: significantly higher expression of cysteinyl leukotriene receptor 2 mRNA in eosinophils. *Clin Exp Allergy* 2001; 31: 1714–23.

# Functional SNPs in the distal promoter of the *ST2* gene are associated with atopic dermatitis

Makiko Shimizu<sup>1,2</sup>, Akira Matsuda<sup>1,\*</sup>, Ken Yanagisawa<sup>3</sup>, Tomomitsu Hirota<sup>1</sup>, Mitsuteru Akahoshi<sup>1</sup>, Naoko Inomata<sup>2</sup>, Kouji Ebe<sup>4</sup>, Keiko Tanaka<sup>5</sup>, Hisashi Sugiura<sup>5</sup>, Kazuko Nakashima<sup>1,6</sup>, Mayumi Tamari<sup>1</sup>, Naomi Takahashi<sup>1</sup>, Kazuhiko Obara<sup>1</sup>, Tadao Enomoto<sup>7</sup>, Yoshimichi Okayama<sup>8</sup>, Pei-Song Gao<sup>9</sup>, Shau-Ku Huang<sup>9</sup>, Shin-ichi Tominaga<sup>3</sup>, Zenro Ikezawa<sup>2</sup> and Taro Shirakawa<sup>1,6</sup>

<sup>1</sup>Laboratory for Genetics of Allergic Diseases, SNP Research Center, RIKEN, Yokohama, Japan, <sup>2</sup>Department of Dermatology, Yokohama City University School of Medicine, Yokohama, Japan, <sup>3</sup>Department of Biochemistry, Jichi Medical School, Tochigi, Japan, <sup>4</sup>Takao Hospital, Kyoto, Japan, <sup>5</sup>Department of Dermatology, Shiga Medical School, Shiga, Japan, <sup>6</sup>Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Public Health, Kyoto, Japan, <sup>7</sup>Department of Otolaryngology, Japanese Red Cross Society, Wakayama Medical Center, Wakayama, Japan, <sup>8</sup>Laboratory of Allergy Transcriptome, Research Center for Allergy and Immunology, RIKEN, Yokohama, Japan and <sup>9</sup>Johns Hopkins Asthma and Allergy Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Received June 15, 2005; Revised and Accepted August 18, 2005

Atopic dermatitis (AD) is a common inflammatory skin disease associated with the local infiltration of T helper type 2 (Th2) cells. The *ST2* gene encodes both membrane-bound ST2L and soluble ST2 (sST2) proteins by alternative splicing. The orphan receptor ST2L is functionally indispensable for Th2 cells. We found a significant genetic association between AD and the –26999G/A single nucleotide polymorphism (SNP) ( $\chi^2$ -test, raw *P*-value = 0.000007, odds ratio 1.86) in the distal promoter region of the *ST2* gene (chromosome 2q12) in a study of 452 AD patients and 636 healthy controls. The –26999A allele common among AD patients positively regulates the transcriptional activity of the *ST2* gene. In addition, having at least one –26999A allele correlated with high sST2 concentrations and high total IgE levels in the sera from AD patients. Thus, the –26999A allele is correlated with an increased risk for AD. We also found that the –26999G/A SNP predominantly affected the transcriptional activity of hematopoietic cells. Immunohistochemical staining of a skin biopsy specimen from an AD patient in the acute stage showed ST2 staining in the keratinocytes as well as in the infiltrating cells in the dermal layer. Our data show that functional SNPs in the *ST2* distal promoter region regulate ST2 expression which induces preferential activation of the Th2 response. Our findings will contribute to the evaluation of one of the genetic risk factors for AD.

## INTRODUCTION

Atopic dermatitis (AD) is a chronic inflammatory skin disease associated with the local infiltration of T helper type 2 (Th2) cells that secrete interleukin (IL)-4, IL-5 and IL-13 in the acute stage followed by the infiltration of T helper type 1 (Th1) cells, which is responsible for the chronicity of AD lesions (1). Genetic susceptibility to AD has been suggested by epidemiological and genetic studies (2–4). In one study,

monozygotic twin pairs had a concordance rate of 0.72 and dizygotic twin pairs had one of 0.23 for AD (5). The IL-1 receptor (IL1R) gene cluster (2q12–14) has many immunoregulatory genes including IL1R1, IL1R2, IL18R1 and IL18RAP. We and others reported some genetic association studies of atopic diseases investigating this region (6–8). We carried out detailed genetic association studies of the IL1R region and found that genetic polymorphisms within the *ST2* (IL1RL1) gene region had a strong association with AD.

\*To whom correspondence should be addressed at: Laboratory for Genetics of Allergic Diseases, SNP Research Center, RIKEN, 1-7-22, Suehiro, Tsurumi-KU, Yokohama 230-0045, Japan. Tel: +81 455039616; Fax: +81 455039615; Email: akimatsu@src.riken.go.jp

ST2 was originally reported as a gene induced by serum in mouse fibroblasts (9). There are three alternatively spliced variants in ST2 in mammals, membrane-bound ST2L (10), soluble ST2 (sST2) (9) and ST2V (11). ST2L is an orphan receptor which has a conserved cytosolic domain called as the Toll-IL1R (TIR) domain. The functional role of ST2L is relevant to AD because ST2L is expressed in Th2 cells but not in Th1 cells (12), it has critical roles in Th2 effector functions (13) and is considered as a functional marker for Th2 cells. In addition, ST2L expression was also reported in mast cells (14), effector cells in the acute stage of AD (15). In contrast to other members of the TIR family that activate NF- $\kappa$ B signaling pathways (16), ST2L negatively regulates IL1R1 and toll-like receptor (TLR)-4 signals by sequestering MyD88 and Mal signals (17). In this study, we found single nucleotide polymorphisms (SNPs) associated with increased risk for AD in the promoter region of the *ST2* gene. The high-risk SNPs showed higher ST2 promoter activity and hence increased serum sST2 as well as total IgE levels in AD patients.

## RESULTS

### Identification of genetic polymorphisms in ST2 and intragenic LD

We discovered 67 genetic variants in the ST2 region (Supplementary Material, Table S2) by resequencing DNA samples from 24 Japanese individuals (12 AD patients and 12 controls). Among the 67 genetic polymorphisms, 34 variants had estimated minor allele frequencies (MAF) of >10% (based on the sequencing of 24 DNA samples). We calculated  $r^2$  as the statistical value for pairwise linkage disequilibrium (LD) between the SNPs (Supplementary Material, Fig. S1). On the basis of location and LD with other sites, we selected seven haplotype tagging SNPs as representative SNPs (Fig. 1A and Table 1) from the 34 common SNPs. Two SNPs (-27639A/G and -26999G/A) were in the 5'-genomic region for exon 1a, one SNP (744C/A) in exon 3 and four SNPs (2992C/T, 5283G/A, 5860C/A, 11147C/T) in the introns. Positions are numbered according to their positions relative to the published *ST2* gene sequence (GenBank accession no. AC007248), and position 1 is the adenine of the first methionine.

### Case-control study

A summary of the case-control association study with representative SNPs is shown in Table 1. All seven SNPs were in Hardy-Weinberg equilibrium in both AD and control groups ( $P > 0.05$ ). One -26999G/A SNP showed a significant association under a dominant model [-26999GG versus G/A + A/A, raw  $P$ -value = 0.000007,  $P = 0.000049$  after Bonferroni correction, odds ratio (OR) = 1.86] (Table 2). The association became stronger (raw  $P$ -value = 0.00000038, corrected  $P = 0.00000027$ , OR = 2.55) for the AD patients with very high serum total IgE levels (IgE > 1700 IU/ml,  $n = 290$ ) (Table 2). Weak association was also observed at -27639A/G SNP (-27639AA versus A/G + G/G, raw  $P$ -value = 0.0001, corrected  $P$ -value = 0.0007). The -27084G/C SNP was also fully genotyped and we found that the -27084G/C and -26999A/G SNPs were in a state of complete LD.

### Haplotype analysis

We also tested the distribution of two- and seven-locus haplotypes in AD and control samples. Among the two-locus haplotypes of the promoter region SNPs (-27639A/G and -26999G/A), haplotype -27639G/-26999A showed an increased risk for AD (Table 3, G, A versus others;  $P = 0.0004$ , OR = 1.41). We also analyzed the haplotypes of the seven representative SNPs and found that haplotype-A was associated with AD (Table 4, haplotype-A versus others;  $P = 0.000028$ , OR = 1.45). However, none of these associations was stronger than those observed for the single locus (-26999G/A).

### Reporter gene analysis


We made a construct for haplotype-1 (the major haplotype: -27639A, -27084G and -26999G) and haplotype-2 (the common haplotype among AD patients: -27639G, -27084C and -26999A) with pGL3 basic vector. The assay was performed in triplicate, and a representative result of three independent experiments is shown as mean  $\pm$  SD in Fig. 1B, right. The relative strengths of luciferase activity were  $1517 \pm 41$  (mean  $\pm$  SD) for haplotype-1 and  $3226 \pm 84$  for haplotype-2,  $267 \pm 7$  for distal- $\Delta$ 355 (-27639A clone). The distal- $\Delta$ 355 clone with the -27639G allele showed a result similar to that for the -27639A allele (data not shown). Haplotype-2 induced stronger ST2 promoter activity than haplotype-1.

### RT-PCR analysis with a panel of hematopoietic cells, keratinocytes and dermal fibroblasts

For analysis of differential promoter usage, we made specific primer sets to distinguish each promoter and subtype of ST2 expression and performed RT-PCR with cDNA from a human mast cell line (LAD2), human keratinocytes (KC) cultured with serum-free medium and dermal fibroblasts cultured with 10% fetal bovine serum (FBS). For some studies, KC were stimulated with 10% FBS for 24 h. The results showed that only mast cells used both distal and proximal promoters. The other cells (skin fibroblasts and KC) used the proximal promoter exclusively (Fig. 1C). LAD2 cells could express sST2 mRNA using both promoters and ST2L mRNA using the distal promoter, whereas skin fibroblasts and KC could only express sST2 using the proximal promoter (Fig. 1C).

### Quantification of sST2 protein and total IgE using the sera from AD patients

The concentration of sST2 in the sera of 124 AD patients was measured with ELISA. The sST2 concentration of the serum of patients with the -26999G/G genotype was 0.225 ng/ml (mean). For the -26999G/A + A/A genotype, it was 0.365 ng/ml (Supplementary Material, Fig. S4A). The sera from -26999G/G genotype patients showed a significantly lower ST2 concentration than those from -26999G/A + A/A patients ( $P = 0.0000008$  by Mann-Whitney  $U$ -test). All measurements were performed in duplicate. We carried out



**Figure 1.** *ST2* gene structures and the roles of promoters in the induction of ST2 transcripts. (A) *ST2* (IL1RL1) locus SNP map in the genomic region. The complete coding region of *ST2*, intron/exon boundaries, ~3 kb of 5'-genomic DNA, is shown. The longer variant (*ST2L*) has 11 exons and the shorter variant (*sST2*) has eight exons. These exons are indicated by closed rectangles. (B) Comparison of allelic variants of the *ST2* distal promoter region analyzed by luciferase activity. Allelic differences in luciferase activity were examined using human mast (LAD2) cells. The constructs of the reporter plasmids are shown on the left. Five hundred nanograms of each plasmid was transfected with 10 ng of pRL-TK vector. Transcriptional activity was determined by assaying the *firefly* luciferase activity of cellular extracts prepared 24 h after transfection. Data show the mean  $\pm$  SD relative activity from a representative experiment done in triplicate. \* $P = 0.004$  by Student's *t*-test. (C) RT-PCR with cDNA from various cells in skin using specific primer sets for distinguishing each promoter and subtype (*ST2L/sST2*) expression. (Top left) Forward primer: exon 1a (distal promoter), reverse primer: *sST2* specific region. (Top right) Forward: exon 1a, reverse: *ST2L*-specific region. (Bottom left) Forward: exon 1b (proximal promoter), reverse: *sST2*. (Bottom right) Forward: exon 1b, Reverse: *ST2L*. Lane 1: LAD2 (mast cells), lane 2: KC cultured with serum-free medium (SFM), lane 3: KC cultured with SFM + 10% FBS for 24 h, lane 4: dermal fibroblasts. M1: 1 kb molecular marker, M2: 100 bp molecular marker.

**Table 1.** Genotype frequencies for ST2 SNPs and AD susceptibility

SNP number	Location	Control (n = 636)					Minor allele frequency	AD (n = 452)					Minor allele frequency	P-value <sup>a</sup>	P-value <sup>b</sup>	P-value <sup>c</sup>
		1	2	3	Sum	1		2	3	Sum						
1	14	-27639A/G	205	295	124	624	0.44	99	235	115	449	0.52	0.0026 <sup>d</sup>	0.0007 <sup>d</sup>	NS	
2	18	-26999G/A	223	279	112	614	0.41	106	240	106	452	0.50	0.00024 <sup>d</sup>	0.000049 <sup>d</sup>	NS	
3	41	744C/A	415	182	28	625	0.19	313	123	9	445	0.16	NS	NS	NS	
4	49	2992C/T	221	286	113	620	0.41	183	205	57	445	0.36	NS	NS	NS	
5	51	5283G/A	272	273	79	624	0.35	204	195	48	447	0.33	NS	NS	NS	
6	57	5860C/A	225	284	110	619	0.41	187	205	56	448	0.35	NS	NS	NS	
7	67	11147C/T	251	280	91	622	0.37	209	189	47	445	0.32	NS	NS	NS	

NS, not significant.

<sup>a</sup>Allele1 versus allele2.<sup>b</sup>Genotype11 versus 12 + 22.<sup>c</sup>Genotype11 + 12 versus 22.<sup>d</sup>P-value statistically significant after Bonferroni correction (raw P-values were multiplied by 7).**Table 2.** Association between ST2-26999 G/A SNP and AD

	Controls (n = 614)	AD (n = 452)	$\chi^2$ (P-value)	OR (95% CI)	AD total IgE > 1700 (n = 290)	$\chi^2$ (P-value)	OR (95% CI)
-26999G/A							
GG	223	106	GG:others 20.20 (0.0000070) <sup>a</sup>	1.86 (1.42–2.45)	53	GG:others 30.23 (0.00000038) <sup>a</sup>	2.55 (1.81–3.58)
GA	279	240			166		
AA	112	106	(0.000049) <sup>b</sup>		71	(0.0000027) <sup>b</sup>	

<sup>a</sup>Raw P-value.<sup>b</sup>P-value after Bonferroni correction.**Table 3.** Haplotype structures and frequencies in ST2 distal promoter

Haplotype	Haplotype frequency		$\chi^2$	P-value	OR
	Case	Control			
-27639, -26999					
A, G	0.56	0.48	13.00	0.0012	1.37
G, A	0.41	0.50	15.14	0.0004	1.41
G, G	0.025	0.019	0.85	0.35	1.32

two separate experiments and the results were similar. The total IgE concentration in the sera of 428 AD patients was measured with the fluorescence-enzyme immunoassay (FEIA) (Supplementary Material, Fig. S4B). The total IgE concentrations were 5371.9 IU/ml (mean) for the sera from -26999G/G genotype patients and 7898.7 IU/ml for those from -26999 G/A + A/A genotype patients. The serum concentration of total IgE was significantly lower in the sera of -26999G/G patients ( $P = 0.0024$  by Mann-Whitney *U*-test). The correlation between the sST2 and the total IgE concentration was examined among -26999A/A genotype patients (Supplementary Material, Fig. S4C); Pearson's correlation coefficient was 0.28.

### ST2L protein expression on the surface of human mast cells

Immunoprecipitation (IP) and subsequent western blotting using LAD2 cell lysate showed a positive band around

90 kDa in the IP samples with an anti-ST2 antibody (clone2A5). Deglycosylation with PNGaseF showed a shift of the band to lower molecular weight, corresponding to the molecular weight of non-glycosylated ST2L protein (Fig. 2A). To further demonstrate the surface expression of ST2L protein, non-stimulated LAD2 cells were stained with the anti-ST2 antibody (with FITC) and analyzed by FACS. The histogram showed a positive shift of the mean FITC intensity of ST2 staining (dotted line, Fig. 2B) compared with that of isotype-matched mouse IgG.

### Immunohistochemistry

A paraffin section of the skin biopsy sample from an AD patient in the acute stage was stained with an anti-ST2 monoclonal antibody (clone HB12). Positive staining was observed on the cell surface of KC in the suprabasal layer and infiltrating cells in the dermal layer (Fig. 3A and C). ST2-positive staining was observed only with the infiltrating cells in the dermal layer of the skin of another AD patient in the chronic stage (Fig. 3B). Immunostaining with control mouse IgG<sub>1</sub> did not show positive signals (data not shown).

### DISCUSSION

We found an SNP in the distal promoter region of ST2 (-26999G/A) that showed a significant association with AD during our series of genetic association studies within the IL1R gene cluster. This is the first association study for the

Table 4. Haplotype structures and frequencies in ST2

HaplotypeID	Haplotype frequency		-27639	-26999	744	2992	5283	5860	11147
	Case	Control							
Haplotype A	0.41	0.5	G	A	C	T	A	C	C
Haplotype B	0.33	0.32	A	G	C	C	G	A	T
Haplotype C	0.13	0.12	A	G	A	T	A	C	C

Haplotype1/others:  $\chi^2 = 17.5$ ;  $P = 0.000028$ ; OR = 1.45.

Haplotype2/others:  $\chi^2 = 0.15$ ;  $P = 0.703$ ; OR = 1.04.

Haplotype3/others:  $\chi^2 = 0.57$ ;  $P = 0.451$ ; OR = 1.1.

*ST2* gene and the results are intriguing, because the SNPs directly affect the expression level of Th2 cell marker ST2. Recent studies have clearly shown essential functional roles of ST2L protein for Th2-mediated immune responses (13,18,19), so it seems reasonable to investigate ST2 genetic polymorphism as a candidate for conferring susceptibility to AD. The result of case-control association studies of seven representative SNPs (Table 1) and haplotype analysis (Tables 3 and 4) showed that the highest association with AD was observed with the -26999G/A SNP as a single locus. There were four other SNPs in the ST2 genomic region that showed tight LD with the -26999G/A SNP. Three SNPs were located distal to the -26999G/A SNP in the distal promoter region. Two SNPs (-28214T/C; 3258 bp distal from the transcription starting site and -29778C/A; 1694 bp distal from the site) were not included in the functional analysis because our series of 5'-deletion promoter assays showed that the critical region for ST2 distal promoter activity was located within 300-500 bp from the transcriptional starting point (20); therefore, these two SNPs seemed to be less functional. Of the remaining two SNPs, one SNP (-27084G/C) was located at 85 bp distal to the -26999G/A SNP (236 bp distal to the transcriptional starting site); therefore, we decided to analyze these two SNPs together by reporter gene assay. The last SNP (-2874A/G) in tight LD with -26999G/A, located in the proximal promoter region of the *ST2* gene, did not affect the proximal promoter activity (Supplementary Material, Fig. S2).


The distal promoter reporter gene assay was performed with two 1132 bp distal promoter constructs, including two major haplotypes -27639A/-27084G/-26999G and -27639G/-27084C/-26999A covering >97% of haplotype frequency (Table 3). In addition to the two SNPs in the state of complete LD, (-27084/-26999), another SNP (-27639 A/G) that also showed a weak association with AD (Table 1) was included for analysis. We have reported that a GATA element commonly observed in both human and mouse *ST2* gene distal promoter region was indispensable for the activation of the promoter activity in Th2 cells (20,21). Therefore, we made another set of promoter assay constructs (Distal- $\Delta$ 355) deprived of the GATA binding site and two SNP sites, which showed abrogated transcriptional activity (Fig. 1B). From these results, we concluded that this 356 bp region was essential for ST2 transcription and that the two SNPs (-27084G/C and -26999G/A) had major influences on the distal promoter activity among the SNPs with significant associations.

For further analysis of the roles of the genetic polymorphisms, we measured the serum concentrations of sST2 and total IgE and sorted the results by the genotype in the distal promoter. As the association study showed the most significant result under a dominant model (Tables 1 and 2), we compared the results by the genotype -26999G/G (low risk for AD) versus -26999A/G + A/A (high risk for AD). The results matched the results of the reporter gene assay and the association study. Furthermore, the genetic association between the -26999G/A SNP and AD patients for very high serum total IgE (IgE > 1700 IU/ml) became stronger (Table 2). These results suggested that having at least one allele of -26999A was correlated with a high sST2 level and a high total IgE concentration and an increased risk for AD. There is some controversy over the role of IgE in the pathogenesis of AD (22); therefore, it will be useful to genotype intrinsic AD (1) patients in the future.

We found a weak correlation ( $r = 0.28$ ) between the serum sST2 level and the total IgE concentration with the genotype -26999AA patients. This finding was consistent with the recent report that the increase of food-specific IgE is paralleled by elevated sST2 levels, not by serum IL-4, IL-13 and interferon gamma levels (23). These results suggested possible effects of sST2 in IgE production, so further studies seem to be essential.


We reported sST2 concentrations of 200 healthy controls and 56 asthmatic patients previously (24). The sST2 concentration of healthy controls was 0-1.65 ng/ml (mean 0.415 ng/ml) and that of asthmatic patients was 0-2.40 ng/ml (mean 0.493 ng/ml). A differential rise of the serum ST2 level that correlated well with the severity of asthma exacerbation was observed (24). The serum concentration of sST2 in AD patients [0-1.02 ng/ml (mean 0.326 ng/ml)] was not significantly higher or lower than that of healthy controls or asthmatics; nonetheless, there was a correlation between the ST2 genotype and the sST2 concentration. We are now investigating the changes of the sST2 concentration during the clinical stages of AD, and the results might further clarify the role of sST2 in AD.

It has been reported that the usage of two different promoters (distal and proximal) depends on the type of cell for the human *ST2* gene (21). Consistent with this report, we showed that only hematopoietic cells utilized the distal promoter and that ST2 transcription of other skin cells (KC, dermal fibroblasts) was initiated from the proximal promoter (Fig. 1C). These results suggested that the significant association of SNPs -27084 and -26999 in the ST2 distal promoter



**Figure 2.** ST2L expression in LAD2 cells. (A) LAD2 cell lysate samples were immunoprecipitated with either an anti-ST2 IgG antibody (2A5) or an isotype-matched control antibody. The immunoprecipitated samples were electrophoresed and immunoblotted with an anti-ST2 IgM antibody (clone: G7). Duplicated samples after IP were treated with PNGaseF for 1 h and then immunoblotted simultaneously. Lane 1: anti-ST2-IP, lane 2: control antibody-IP, lane 3: control antibody-IP-PNGaseF-treated, lane 4: anti-ST2-IP-PNGaseF-treated. (B) Cell surface ST2L protein expression in LAD2 was analyzed with a FACS Calibur. FcR of LAD2 cells were blocked and then stained with an anti-ST2 antibody (2A5). FITC-goat anti-mouse IgG1 was used as the secondary antibody. Staining with control mouse IgG1 is shown with a black line and the anti-ST2 antibody is shown with the dotted red line.

region predominantly affected hematopoietic cells. We found that both ST2L and sST2 mRNAs were expressed most abundantly in mast cells (Supplementary Material, Fig. S3) and confirmed ST2L expression on mast cells at the protein level by western blotting (Fig. 2A) and FACS analysis (Fig. 2B). Moritz *et al.* (14) reported that ST2L was selectively expressed during the development of mast cell lineage, and very recently Chen *et al.* (25) showed that



**Figure 3.** Immunohistochemical staining of human skin samples obtained from AD patients with anti-ST2 monoclonal antibody. Paraffin sections of AD skin biopsies were immunostained with an anti-ST2 antibody (HB12). (A) Skin biopsy from acute stage AD. Suprabasal layers of KC show membranous ST2-positive staining. Sporadic positive staining in the dermal region was also observed. (B) Skin biopsy from chronic stage AD. Some of the infiltrating cells in the dermal layer show positive ST2 staining. (C) High magnification of anti-ST2 immunostaining with acute stage AD. The arrowheads indicate the limit of basement membrane. Bar = 200  $\mu$ m.

ST2L could be one of the markers for mast cell progenitors in adult mice. These results suggested that abundant ST2L expression might positively affect the number of mature mast cells in the skin, as observed in the AD skin region

(26). The functional roles of ST2L in mast cells will be clarified with an ST2L overexpression system (10), and a study is ongoing.

The positive immunostaining around the cell membrane of suprabasal KC in the acute stage of AD (Fig. 3A and C) reflects the accumulated sST2 in intercellular space because ST2L mRNA expression in KC was not observed in experiments *in vitro*. This is consistent with a previous study that showed intense ST2 protein accumulation in mouse epidermis (27), and we think that serum extravasation during the acute stage of AD may induce sST2 expression in KC as observed in our *in vitro* study (Fig. 1C) (Supplementary Material, Fig. S3). On the other hand, a histological sample from the chronic phase of AD showed slight ST2 staining (Fig. 3B). This might be a reflection of the shift toward the Th1 dominant immunological character observed in the chronic stage of AD (1,28).

Another clinical feature of AD is a reduced skin innate immune response (1). ST2L expression could inhibit the TLR-dependent innate response by sequestering the adaptor molecules Myd88 and Mal (17). Several reports showed that both anti-ST2 antibodies and ST2-immunoglobulin fusion protein could abrogate the Th2 immune response and eosinophilic responses (18,29). Therefore, we consider that sST2/ST2L will be a good therapeutic target of AD and that understanding of the genetic predisposition for high ST2 promoter activity may contribute to the prevention of severe AD.

## MATERIALS AND METHODS

### Antibodies and cell lines

Anti-ST2 monoclonal antibodies (mouse IgG1; clones 2A5 and HB12) were purchased from MBL (Nagoya, Japan), and an anti-ST2 monoclonal antibody (mouse IgM; clone G7) was generated as previously described (30). Human mast cell line LAD2 was kindly provided by Dr Arnold Kirshenbaum (NIAID, NIH) and maintained as previously described (31). Human neonatal skin fibroblasts were obtained from RIKEN cell bank (Tsukuba, Japan), immortalized human normal keratinocyte cells (PHK16-06b) were obtained from the Japanese Collection of Research Bioresources (JCRB) cell bank (Osaka, Japan).

### Subjects

All subjects with AD were diagnosed according to the criteria of Hanifin and Rajka (32). Peripheral blood was obtained from 452 AD patients (mean age 30.0, 11–64 years old at enrollment of the study; mean age 7.1, 0–45 years old at the onset of AD; 236 males and 216 females) from Takao Hospital, Shiga Medical College Hospital and Yokohama City University Hospital. Sera for sST2 ELISA assay were also obtained from some of the patients enrolled in this genetic study. As a control group, we analyzed 636 randomly selected population-based individuals (mean age 42.2, 18–70 years). We excluded the presence of asthma, AD and nasal allergy in the control population via careful interview by physicians. All individuals were Japanese and gave written informed

consent to participate in the study (or, for individuals less than 16 years old, their parents gave consent), according to the rules of the process committee at SNP Research Center, RIKEN.

### Screening for genetic polymorphisms

The ST2 genomic region targeted for SNP discovery included a 2.5 kb continuous region 5' to exon 1a (distal promoter region) and a 2.5 kb continuous region 5' to exon 1b (proximal promoter region) and 11 exons, each with a minimum of 200 bases of flanking intronic sequences (Fig. 1A). Primer sets (Supplementary Material, Table S1) were designed on the basis of the ST2 genomic sequence (GenBank accession no. AC007248). Each polymerase chain reaction (PCR) was carried out with 5 ng of genomic DNA from 24 individuals. Sequence reaction was performed with Big Dye Terminator v3.1 using an ABI 3700 DNA analyzer.

### Genotyping

We genotyped a total of seven representative SNPs in the ST2 gene selected on the basis of the allele frequency (MAF > 10%) and LD (Table 1) (Supplementary Material, Table S2 and Fig. S1). Additional typing was carried out for some SNPs, in relation to the functional assay for ST2 genes. The SNP typing was carried out either with the invader assay (33) or with the Taqman genotyping assay using an ABI PRISM 7700 sequence detection system. Invader assay was performed with multiplex PCR products as the template. Taqman genotyping assay was carried out according to the manufacturer's protocol.

### Statistical analysis

Allele frequencies in AD cases and controls were compared by the contingency  $\chi^2$ -test. A *P*-value of less than 0.01, also in the case of multiple comparisons after Bonferroni adjustment, was considered to be statistically significant. ORs and 95% confidence intervals (95% CI) were calculated. Pairwise LD coefficients were calculated and expressed as  $r^2$ . Intragenic LD and haplotype analyses were performed using SNPalyze v2.0 (DYNACOM, Chiba, Japan) as recommended by the manufacturer. We estimated haplotype frequencies using the expectation-maximization algorithm. Comparison in reporter gene assay was performed with Student's *t*-test. The association between the serum sST2 level or total IgE concentration and the genotype was evaluated by the Mann-Whitney *U*-test. A *P*-value of less than 0.05 was considered to be statistically significant.

### Reporter gene assay

We subcloned 1131 bp distal promoter sequences continuous to exon 1a into pGL3 basic vector (Promega Corporation, Madison, WI, USA). Two SNPs in this region (–27084G/C and –26999G/A) were in the state of complete LD. We made two haplotype clones 1 (–27639A, –27084G, –26999G) and 2 (–27639G, –27084C, –26999A). Another set of constructs was made by deleting a 355 bp long promoter sequence

between two PstI sites, which contained the -27084G/C and -26999G/A SNPs as well as two putative GATA binding sequences (named distal-Δ355). All subcloned plasmids were verified by direct sequencing. We transfected the pGL3-ST2 promoter plasmid and pRL-TK renilla luciferase vector (Promega) as an internal control for transfection efficiency into human cell line LAD2 with DMR1E-C (Invitrogen, Carlsbad, CA, USA). After 24 h, luciferase activity was measured with a Dual Luciferase Reporter Assay Kit (Promega).

#### Measurement of sST2 protein and total IgE

The protein level of sST2 in the sera of AD patients was measured using human ST2 ELISA kits (MBL) following the manufacturer's protocol. The total IgE concentration in serum was measured by the FEIA method in a commercial laboratory.

#### RT-PCR analysis for differential promoter usage

mRNA was isolated from cultured cells (LAD2, KC and human dermal fibroblasts) with a Quick Prep micro-mRNA purification kit (Amersham Bioscience, Little Chalfont, UK). cDNA was made with the Super Script III First-Strand Synthesis System (Invitrogen) using oligo(dT)<sub>20</sub> primer. To distinguish promoter usage for specific cell types and subtypes (sST2/ST2L) of mRNA, we made sets of specific primers and performed RT-PCR as previously described (21).

#### IP and western blotting analysis

First,  $1 \times 10^7$  LAD2 cells were solubilized with lysis buffer [1% Triton X-100 in 20 mM Tris-HCl, pH 7.6, 150 mM NaCl with Complete Mini protease inhibitor cocktail tablets (Roche, Penzberg, Germany)]. The cell lysate was centrifuged at 20 000g for 15 min at 4°C. The supernatant was taken and pre-cleared with Protein-A Sepharose (Amersham) for 30 min. The sample was reacted with 2 μg of the anti-ST2 antibody (2A5) or control mouse IgG1 for 1 h and then Protein-A Sepharose was added. After 3 h rotation at 4°C, the Sepharose was washed with the lysis buffer and finally suspended with SDS sample buffer (50 mM Tris-HCl, pH 6.8, 2% SDS, 20% glycerol, 0.4% bromophenol blue, 50 mM DTT). To check the glycosylation status of ST2L protein, aliquots of the IP samples were treated with PNGaseF (New England Biolaboratory, Beverly, MA, USA). SDS-PAGE and subsequent immunoblotting were essentially performed as previously described (34). In brief, samples were subjected to SDS-PAGE using 4–20% Tris-glycine polyacrylamide gels and then electrophoretically transferred onto a PVDF membrane (Millipore). The membrane was incubated with the mouse anti-human ST2 IgM antibody (G7) overnight at 4°C. After washing with PBS, the membrane was reacted with a horseradish peroxidase (HRP)-conjugated anti-mouse IgM antibody for 30 min. The membrane was developed onto X-ray film with ECL plus (Amersham).

#### Flow cytometric analysis

Flow cytometric analysis was carried out using the anti-ST2 monoclonal antibody (2A5). LAD2 cells were washed with

PBS, and Fc receptors (FcR) were blocked with FcR blocking reagent (Miltenyi Biotec, Gladbach, Germany). Cells were reacted with 4 μg of the anti-ST2 IgG monoclonal antibody in a volume of 40 μl for 15 min at room temperature. As a control, an isotype-matched mouse IgG1 antibody was used. After washing with PBS, the cells were reacted with an FITC-conjugated anti-mouse IgG antibody (Dako Japan, Kyoto). The stained cells were analyzed with a FACS Caliber (BD Japan).

#### Immunohistochemistry

ST2 immunohistochemistry was performed essentially as described previously (35). In brief, formaldehyde-fixed paraffin sections of the skin biopsies from AD patients were deparaffinized, then the endogenous peroxidase activity was quenched with 0.3% H<sub>2</sub>O<sub>2</sub> in methanol for 20 min. Non-specific staining was blocked with blocking buffer (10% normal goat serum, 1% BSA in PBS) for 30 min. The anti-ST2 monoclonal antibody (clone HB12) was applied and reacted overnight at 4°C. After washing with PBS, slides were incubated with HRP-conjugated anti-mouse IgG for 30 min. The slides were developed with DAB (Dojindo, Kumamoto, Japan).

#### SUPPLEMENTARY MATERIAL

Supplementary Material is available at HMG Online.

#### ACKNOWLEDGEMENTS

We thank Dr Arnold Kirshenbaum for providing LAD2 cells, Professor Julian M. Hopkin for continuous supports and valuable comments, Miki Kokubo and Hiroshi Sekiguchi for their excellent technical assistance. This work was supported by a grant from the Japanese Millennium Project.

*Conflict of Interest statement.* None declared.

#### REFERENCES

- Leung, D.Y., Boguniewicz, M., Howell, M.D., Nomura, I. and Hamid, Q.A. (2004) New insights into atopic dermatitis. *J. Clin. Invest.*, **113**, 651–657.
- Lee, Y.A., Wahn, U., Kehrt, R., Tarani, L., Businco, L., Gustafsson, D., Andersson, F., Oranje, A.P., Wolkertstorfer, A., Von Berg, A. *et al.* (2000) A major susceptibility locus for atopic dermatitis maps to chromosome 3q21. *Nat. Genet.*, **26**, 470–473.
- Bradley, M., Soderhall, C., Luthman, H., Wahlgren, C.F., Kockum, I. and Nordenskjold, M. (2002) Susceptibility loci for atopic dermatitis on chromosomes 3, 13, 15, 17 and 18 in a Swedish population. *Hum. Mol. Genet.*, **11**, 1539–1548.
- Cookson, W.O., Ubhi, B., Lawrence, R., Abecasis, G.R., Walley, A.J., Cox, H.E., Coleman, R., Leaves, N.I., Trembath, R.C., Moffatt, M.F. *et al.* (2001) Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility loci. *Nat. Genet.*, **27**, 372–373.
- Schultz Larsen, F. (1993) Atopic dermatitis. A genetic-epidemiologic study in a population-based twin sample. *J. Am. Acad. Dermatol.*, **28**, 719–723.
- Mao, X.Q., Kawai, M., Yamashita, T., Enomoto, T., Dake, Y., Sasaki, S., Kataoka, Y., Fukuzumi, T., Endo, K., Sano, H. *et al.* (2000) Imbalance production between interleukin-1beta (IL-1beta) and IL-1 receptor antagonist (IL-1Ra) in bronchial asthma. *Biochem. Biophys. Res. Commun.*, **276**, 607–612.

7. Karjalainen, J., Hulkkonen, J., Pessi, T., Huhtala, H., Nieminen, M.M., Aromaa, A., Klaukka, T. and Hurme, M. (2002) The IL1A genotype associates with atopy in nonasthmatic adults. *J. Allergy. Clin. Immunol.*, **110**, 429–434.
8. Wjst, M., Fischer, G., Immervoll, T., Jung, M., Saar, K., Rueschendorf, F., Reis, A., Ulbrecht, M., Gomolka, M., Weiss, E.H. *et al.* (1999) A genome-wide search for linkage to asthma. German Asthma Genetics Group. *Genomics*, **58**, 1–8.
9. Tominaga, S. (1989) A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. *FEBS Lett.*, **258**, 301–304.
10. Li, H., Tago, K., Io, K., Kuroiwa, K., Arai, T., Iwahana, H., Tominaga, S. and Yanagisawa, K. (2000) The cloning and nucleotide sequence of human ST2L cDNA. *Genomics*, **67**, 284–290.
11. Tominaga, S., Kuroiwa, K., Tago, K., Iwahana, H., Yanagisawa, K. and Komatsu, N. (1999) Presence and expression of a novel variant form of ST2 gene product in human leukemic cell line UT-7/GM. *Biochem. Biophys. Res. Commun.*, **264**, 14–18.
12. Yanagisawa, K., Naito, Y., Kuroiwa, K., Arai, T., Furukawa, Y., Tomizuka, H., Miura, Y., Kasahara, T., Tetsuka, T. and Tominaga, S. (1997) The expression of ST2 gene in helper T cells and the binding of ST2 protein to myeloma-derived RPMI8226 cells. *J. Biochem. (Tokyo)*, **121**, 95–103.
13. Lohning, M., Stroehmann, A., Coyle, A.J., Grogan, J.L., Lin, S., Gutierrez-Ramos, J.C., Levinson, D., Radbruch, A. and Kamradt, T. (1998) T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. *Proc. Natl Acad. Sci. USA*, **95**, 6930–6935.
14. Moritz, D.R., Rodewald, H.R., Gheyselinck, J. and Klemenz, R. (1998) The IL-1 receptor-related T1 antigen is expressed on immature and mature mast cells and on fetal blood mast cell progenitors. *J. Immunol.*, **161**, 4866–4874.
15. Wollenberg, A. and Bieber, T. (2000) Atopic dermatitis: from the genes to skin lesions. *Allergy*, **55**, 205–213.
16. Trajkovic, V., Sweet, M.J. and Xu, D. (2004) T1/ST2—an IL-1 receptor-like modulator of immune responses. *Cytokine Growth Factor Rev.*, **15**, 87–95.
17. Brint, E.K., Xu, D., Liu, H., Dunne, A., McKenzie, A.N., O'Neill, L.A. and Liew, F.Y. (2004) ST2 is an inhibitor of interleukin 1 receptor and toll-like receptor 4 signaling and maintains endotoxin tolerance. *Nat. Immunol.*, **5**, 373–379.
18. Coyle, A.J., Lloyd, C., Tian, J., Nguyen, T., Eriksson, C., Wang, L., Ottoson, P., Persson, P., Delaney, T., Lehar, S. *et al.* (1999) Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. *J. Exp. Med.*, **190**, 895–902.
19. Xu, D., Chan, W.L., Leung, B.P., Huang, F., Wheeler, R., Piedrafita, D., Robinson, J.H. and Liew, F.Y. (1998) Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. *J. Exp. Med.*, **187**, 787–794.
20. Hayakawa, M., Yanagisawa, K., Aoki, S., Hayakawa, H., Takezako, N. and Tominaga, S. (2005) T-helper type 2 cell-specific expression of the ST2 gene is regulated by transcription factor GATA-3. *Biochim. Biophys. Acta*, **1728**, 53–64.
21. Iwahana, H., Yanagisawa, K., Ito-Kosaka, A., Kuroiwa, K., Tago, K., Komatsu, N., Katashima, R., Itakura, M. and Tominaga, S. (1999) Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. *Eur. J. Biochem.*, **264**, 397–406.
22. Halbert, A.R., Weston, W.L. and Morelli, J.G. (1995) Atopic dermatitis: is it an allergic disease? *J. Am. Acad. Dermatol.*, **33**, 1008–1018.
23. Untersmayr, E., Bakos, N., Scholl, I., Kundi, M., Roth-Walter, F., Szalai, K., Riemer, A.B., Ankersmit, H.J., Scheiner, O., Boltz-Nitulescu, G. *et al.* (2005) Anti-ulcer drugs promote IgE formation toward dietary antigens in adult patients. *FASEB J.*, **19**, 656–658.
24. Oshikawa, K., Kuroiwa, K., Tago, K., Iwahana, H., Yanagisawa, K., Ohno, S., Tominaga, S.I. and Sugiyama, Y. (2001) Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. *Am. J. Respir. Crit. Care Med.*, **164**, 277–281.
25. Chen, C.C., Grimbaldston, M.A., Tsai, M., Weissman, I.L. and Galli, S.J. (2005) Identification of mast cell progenitors in adult mice. *Proc. Natl Acad. Sci. USA*, **102**, 11408–11413.
26. Damsgaard, T.E., Olesen, A.B., Sorensen, F.B., Thestrup-Pedersen, K. and Schiotz, P.O. (1997) Mast cells and atopic dermatitis. Stereological quantification of mast cells in atopic dermatitis and normal human skin. *Arch. Dermatol. Res.*, **289**, 256–260.
27. Rossler, U., Thomassen, E., Hultner, L., Baier, S., Danescu, J. and Werenskiold, A.K. (1995) Secreted and membrane-bound isoforms of T1, an orphan receptor related to IL-1-binding proteins, are differently expressed *in vivo*. *Dev. Biol.*, **168**, 86–97.
28. Grewe, M., Bruijnzeel-Koomen, C.A., Schopf, E., Thepen, T., Langeveld-Wildschut, A.G., Ruzicka, T. and Krutmann, J. (1998) A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. *Immunol. Today*, **19**, 359–361.
29. Walzl, G., Matthews, S., Kendall, S., Gutierrez-Ramos, J.C., Coyle, A.J., Openshaw, P.J. and Hussell, T. (2001) Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)-but not Th1-driven immunopathology. *J. Exp. Med.*, **193**, 785–792.
30. Yoshida, K., Arai, T., Yokota, T., Komatsu, N., Miura, Y., Yanagisawa, K., Tetsuka, T. and Tominaga, S. (1995) Studies on natural ST2 gene products in the human leukemic cell line UT-7 using monoclonal antihuman ST2 antibodies. *Hybridoma*, **14**, 419–427.
31. Kirshenbaum, A.S., Akin, C., Wu, Y., Rottem, M., Goff, J.P., Beaven, M.A., Rao, V.K. and Metcalfe, D.D. (2003) Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI. *Leuk. Res.*, **27**, 677–682.
32. Hanifin, J.M. and Rajka, R.G. (1980) Diagnostic features of atopic dermatitis. *Acta Derm. Venereol.*, **92** (suppl.), 44–47.
33. Ohnishi, Y., Tanaka, T., Ozaki, K., Yamada, R., Suzuki, H. and Nakamura, Y. (2001) A high-throughput SNP typing system for genome-wide association studies. *J. Hum. Genet.*, **46**, 471–477.
34. Matsuda, A., Tagawa, Y., Matsuda, H. and Nishihira, J. (1996) Identification and immunohistochemical localization of macrophage migration inhibitory factor in human cornea. *FEBS Lett.*, **385**, 225–228.
35. Tsuchiya, T., Ohshima, K., Karube, K., Yamaguchi, T., Suefuji, H., Hamasaki, M., Kawasaki, C., Suzumiya, J., Tomonaga, M. and Kikuchi, M. (2004) Th1, Th2, and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL. *Blood*, **103**, 236–241.

# Association of the *IL12RB1* promoter polymorphisms with increased risk of atopic dermatitis and other allergic phenotypes

Naomi Takahashi<sup>1,2</sup>, Mitsuteru Akahoshi<sup>1,3,\*</sup>, Akira Matsuda<sup>1</sup>, Kouji Ebe<sup>4</sup>, Naoko Inomata<sup>5</sup>, Kazuhiko Obara<sup>1,6</sup>, Tomomitsu Hirota<sup>1</sup>, Kazuko Nakashima<sup>1,7</sup>, Makiko Shimizu<sup>1</sup>, Mayumi Tamari<sup>1</sup>, Satoru Doi<sup>8</sup>, Akihiko Miyatake<sup>9</sup>, Tadao Enomoto<sup>10</sup>, Hitoshi Nakashima<sup>3</sup>, Zenro Ikezawa<sup>5</sup> and Taro Shirakawa<sup>1,7</sup>

<sup>1</sup>Laboratory for Genetics of Allergic Diseases, SNP Research Center, RIKEN, Kanagawa 230-0045, Japan, <sup>2</sup>Department of Dermatology, School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan, <sup>3</sup>Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, <sup>4</sup>Takao Hospital, Kyoto, Japan, <sup>5</sup>Department of Dermatology, Yokohama City University School of Medicine, Kanagawa, Japan, <sup>6</sup>Hitachi Chemical Co., Ltd, Tokyo, Japan, <sup>7</sup>Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Public Health, Kyoto, Japan, <sup>8</sup>Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan, <sup>9</sup>Miyatake Asthma Clinic, Osaka, Japan and <sup>10</sup>Department of Otolaryngology, Japanese Red Cross Society Wakayama Medical Center, Wakayama, Japan

Received August 4, 2005; Revised and Accepted September 9, 2005

**Atopic dermatitis (AD) is frequently associated with eosinophilia, highly elevated immunoglobulin E (IgE) levels and increased levels of T-helper 2-type (Th2) cytokines in skin lesions due to infiltrating T cells. Interleukin-12 (IL-12), in combination with interferon- $\gamma$  (IFN- $\gamma$ ), inhibits IgE synthesis and Th2 cell function. As the IFN- $\gamma$ -inducing cytokines IL-12 and IL-23 utilize IL-12R $\beta$ 1 as part of their receptors, it is possible that polymorphic variants of the IL-12R $\beta$ 1 (*IL12RB1*) gene might determine an individual's susceptibility to AD. Here, we carried out a systemic search for genetic variants of the human *IL12RB1* in Japanese subjects and identified 48 genetic variants. In a case-control association study, we found that promoter polymorphisms -111A/T and -2C/T were significantly associated with an increased risk of AD under a recessive model. The -111T-allele frequency in the independent population of child asthmatics was also much higher than that in the control group. In addition, the -111T/T genotype was progressively more common in AD with high total serum IgE levels in an IgE-level-dependent manner. Deletion analysis of the *IL12RB1* promoter suggested that the -265 to -104 region that contained the -111A/T polymorphic site harbored an important regulatory element. Furthermore, we showed that the -111A/T substitution appeared to cause decreased gene transcriptional activity such that cells from -111A/A individuals exhibited higher *IL12RB1* mRNA levels than those from -111T allele carriers. Our results suggested that in individuals with the -111T/T genotype, reduced IL-12R $\beta$ 1 expression may lead to increased Th2 cytokine production in the skin and contribute to the development of AD and other subsequent allergic diseases.**

\*To whom correspondence should be addressed at: Laboratory for Genetics of Allergic Diseases, SNP Research Center, RIKEN Yokohama Institute, RIKEN, 1-7-22 Suhiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan. Tel: +81 455039616; Fax: +81 455039615; Email: akahoshi@src.riken.jp

## INTRODUCTION

Atopic dermatitis (AD) is a chronic inflammatory skin disease primarily occurring in infants and children, which is characterized by pruritic and eczematous skin lesions at characteristic locations (1). Although its prevalence has increased 2–3-fold during the past three decades in industrialized countries, wide variations in prevalence rates have been observed within countries inhabited by groups with similar genetic backgrounds, suggesting that environmental factors may be critical in determining AD onset (2,3). Nonetheless, it is widely accepted that AD has a genetic component responsible for its high familial occurrence. Twin studies of AD have shown concordance rates of 72–86% in monozygotic and 21–23% in dizygotic twin pairs (4,5) such that genetic factors also play an important role in AD development. Taken together, it appears that changes in environmental exposure *in utero* and during the early years of life may lead to the manifestation of AD in genetically predisposed individuals (6).

AD is frequently associated with blood eosinophilia and highly elevated immunoglobulin E (IgE) levels. Biopsies from clinically unaffected skin from AD patients demonstrate increased number of T-helper 2-type (Th2) cells that express interleukin-4 (IL-4) and IL-13, but not interferon- $\gamma$  (IFN- $\gamma$ ), mRNA when compared with normal non-atopic skin (7,8). When compared with normal or uninvolved AD skin, acute AD skin lesions exhibit significantly increased number of IL-4, IL-5 and IL-13 mRNA-expressing cells. Furthermore, transgenic mice genetically engineered to over express IL-4 in their skin and to develop inflammatory pruritic skin lesions similar to AD, which suggests that local skin expression of Th2 cytokines plays a critical role in AD (9).

IL-12, primarily produced by antigen-presenting cells, is a heterodimeric cytokine consists of two disulfide-linked subunits designated as p35 and p40. It plays a central role in regulating Th1 differentiation and in promoting cell-mediated immunity (10). Conversely, IL-12, in combination with IFN- $\gamma$ , inhibits IgE synthesis and antagonizes Th2 differentiation, including the production of Th2 cytokines such as IL-4 (11). The IL-12 receptor (IL-12R) consists of at least two distinct subunits,  $\beta$ 1 and  $\beta$ 2, and is primarily expressed on activated T and NK cells (12). Co-expression of human IL-12R $\beta$ 1 and IL-12R $\beta$ 2 is required for the formation of high-affinity IL-12 binding sites, and analysis of IL-12R-deficient mice showed that both subunits were essential for IL-12R function (13,14). Recently, it was reported that IL-12R $\beta$ 1 is also a component of the receptor complex for another IFN- $\gamma$ -inducing cytokine, IL-23 (15).

To date, case–control association studies have found significant associations between AD and gene polymorphisms in *IL4*, *IL4R*, *IL13*, *RANTES* (*CCL5*), *TGFB1*, *GMCSF* (*CSF2*), *CARD15*, *FCER1B* (*MS4A2*), *SPINK5* and *IL12B* (3,16–18). Although few studies have examined the association between Th1-related genes and the development of AD, there have been recent epidemiological studies showing an inverse relationship between AD and Th1-associated phenotypes. For example, AD was inversely associated with insulin-dependent diabetes mellitus, a Th1-biased autoimmune disorder (19). Moreover, a strong inverse association was also

found between positive tuberculin responses and a range of atopic symptoms, including AD (20). Therefore, we hypothesized that functional single nucleotide polymorphisms (SNPs) in Th1-related genes encoding the IL-12 family of cytokines and cytokine receptors might also contribute to AD susceptibility. To test this hypothesis and to assess the role of IL-12/IL-12R and IL-23/IL-23R systems in AD, we examined the influence of IL-12 $\beta$ 1 (*IL12RB1*) gene polymorphisms in AD susceptibility in the Japanese population.

## RESULTS

### Identification of sequence variants in *IL12RB1*

Direct DNA sequencing revealed 48 *IL12RB1* variants, which included previously reported variants (21–24) and 10 novel variants (–3966C/A, –2163C/T, –1973C/T, –355G/A, 3377C/A, 5854G/A, 9354G/T, 10129G/A, 18205C/T and 20228G/A) in Japanese (Table 1). We identified nine variants in the 5'-flanking region, nine in the coding region (seven non-synonymous and two synonymous), one in the 5'-untranslated region (UTR), one in the 3'-UTR, 21 within introns and seven at the 3' end. Twelve of the 48 variants had estimated minor allele frequencies (MAFs) of <10% (on the basis of the sequencing of 24 DNA samples). Nucleotide position one (+1) was defined as the first adenine of the initiation codon (ATG) and positions for other SNPs were described relative to the ATG on genome contig AC020904. A graphical overview of the structure of the human *IL12RB1* gene with the location of the 36 common polymorphisms (MAF  $\geq$  10%) identified in this study is shown in Figure 1A.

### LD and case–control comparisons

For the successfully genotyped 35 of 36 common variants, we calculated both  $D'$  and  $r^2$  as statistical values for pair-wise linkage disequilibrium (LD) analysis between SNPs. The LD block structure defined by the 35 genotyped SNPs is shown in Figure 1B. Strong LD was detected across the *IL12RB1* region, although at least two historical recombination events seem to have occurred, which divided the region into three strongly correlated LD blocks. Next, on the basis of location and LD with other sites ( $r^2 < 0.9$ ), we selected eight representative SNPs (–111A/T, –2C/T, 4443C/T, 5970G/C, 17183T/C, 17369C/T, 25748T/C and 27637A/T) from the 36 common polymorphisms for further genotyping and association studies in our AD population. The distribution of all eight SNPs was in Hardy–Weinberg equilibrium in both AD and control groups ( $P > 0.05$ ).

For the case–control association study, we genotyped the eight selected SNPs in a set of 382 unrelated individuals with AD and 658 population-based controls. The clinical characteristics of our AD patients are summarized in Table 2. Allele and genotype frequencies of each selected SNP were compared between the patients and the normal controls using the  $\chi^2$  test under different association models. We found a significant association between two promoter SNPs at –111 and –2 (–111A/T and –2C/T) and AD in our Japanese cohort under a recessive model (–111AA + AT versus TT,  $P = 0.00044$ ; –2CC + CT versus TT,  $P = 0.00075$ ; Table 3).

Table 1. Overview of *IL12RB1* variants identified in Japanese

Number	RefSNP ID	JSNP ID	Position	Variation	Location	Amino acid change	Minor allele frequency <sup>a</sup>	Genotyping method	Primers <sup>b</sup>
1	Novel	—	-3966	C/A	5'g	—	0.021 <sup>c</sup>		F1R1
2	rs374326	—	-3633	A/G	5'g	—	0.043 <sup>c</sup>		F2R2
3	rs845331	—	-2252	G/T	5'g	—	0.167		F4R4
4	Novel	—	-2163	C/T	5'g	—	0.042 <sup>c</sup>		F4R4
5	rs447259	—	-2060	A/G	5'g	—	0.167		F4R4
6	rs845329	—	-2004	A/G	5'g	—	0.167		F4R4
7	Novel	—	-1973	C/T	5'g	—	0.042 <sup>c</sup>		F4R4
8	Novel	—	-355	G/A	5'g	—	0.042 <sup>c</sup>		F7R7
9	rs393548	063138	-111 <sup>d</sup>	A/T	5'g	—	0.167	Invader	F8R8
10	rs436857	063137	-2 <sup>d</sup>	C/T	5'-UTR	—	0.146	Invader	F8R8
11	Novel	—	3377	C/A	Exon 2	P37T	0.022 <sup>c</sup>		F9R9
12	rs2305743	063136	4443 <sup>d</sup>	C/T	Intron 2	—	0.188	Invader	F10R10
13	Novel	—	5854	G/A	Exon 4	A91T	0.024 <sup>c</sup>		F11R11
14	rs11086087	—	5970 <sup>d</sup>	G/C	Exon 4	V129V	0.188	TaqMan	F11R11
15	rs2305742	063135	6193	T/G	Intron 4	—	0.139		F11R11
16	rs17880761	—	8895	T/C	Intron 4	—	0.229		F12R12
17	Novel	—	9354	G/T	Intron 5	—	0.022 <sup>c</sup>		F12R12
18	rs382634	—	10072	C/T	Intron 5	—	0.375		F13R13
19	Novel	—	10129	G/A	Intron 5	—	0.208		F13R13
20	rs17885316	—	10809	Ins A	Intron 6	—	0.217		F13R13
21	rs429774	—	10882	A/G	Intron 6	—	0.375		F13R13
22	rs11575934	—	11016	A/G	Exon 7	Q214R	0.375		F13R13
23	—	—	11059	C/T	Exon 7	P228P	0.375		F13R13
24	rs3761041	114595	13717	G/A	Intron 8	—	0.229		F14R14
25	rs391410	—	16988	C/T	Intron 9	—	0.348		F16R16
26	rs375947	063134	17183 <sup>d</sup>	T/C	Exon 10	M365T	0.375	Invader	F16R16
27	rs401502	063133	17221	G/C	Exon 10	G378R	0.375		F16R16
28	rs17882636	063132	17369 <sup>d</sup>	C/T	Intron 10	—	0.146	TaqMan	F16R16
29	rs2305740	063131	17398	T/C	Intron 10	—	0.146		F16R16
30	rs2305739	063130	17440	C/T	Intron 10	—	0.146		F16R16
31	rs12150884	—	17661	C/T	Intron 10	—	0.146		F16R16
32	Novel	—	18205	C/T	Intron 10	—	0.021 <sup>c</sup>		F17R17
33	Novel	—	20228	G/A	Exon 12	—	0.021 <sup>c</sup>		F18R18
34	—	—	22903	G/A	Exon 13	—	0.021 <sup>c</sup>		F19R19
35	rs17878533	—	24793	T/C	Intron 14	—	0.146		F20R20
36	rs383483	—	25748 <sup>d</sup>	T/C	Intron 15	—	0.438	TaqMan	F21R21
37	rs17882370	—	26460	T/C	Intron 15	—	0.063 <sup>c</sup>		F22R22
38	rs1870063	114596	26672	G/A	Intron 15	—	0.125		F22R22
39	—	—	26954	C/T	Intron 15	—	0.125		F22R22
40	—	—	26977	G/T	Intron 15	—	0.125		F22R22
41	rs3746190	097709	27250	C/T	Exon 17	3-UTR	0.125		F23R23
42	rs3833286	097710	27366	Ins G	3'g	—	0.479		F23R23
43	rs404733	097711	27637 <sup>d</sup>	T/A	3'g	—	0.458	Invader	F24R24
44	rs11307847	—	28184	G/T	3'g	—	0.167		F25R25
45	rs5014130	—	28189	C/G	3'g	—	0.438		F25R25
46	rs5827394	—	28191	Del G	3'g	—	0.438		F25R25
47	rs445521	—	28320	A/C	3'g	—	0.438		F25R25
48	rs382410	—	28960	T/C	3'g	—	0.354		F25R25

<sup>a</sup>On the basis of the sequencing of 24 DNA samples.


<sup>b</sup>Primer sequences are listed in Supplementary Material, Table S1.

<sup>c</sup>Variations with MAF of <10%.

<sup>d</sup>SNPs genotyped in a larger population.

The result for each SNP remained significant after correction for multiple tests (corrected  $P$ :  $P_c = 0.0035$  for -111A/T and  $P_c = 0.006$  for -2C/T). Homozygotes for the -111T or -2T alleles were significantly more common in AD patients when compared with controls. Odds ratios (ORs) of developing AD with respect to positions -111 and -2 were 2.46 (95%CI 1.47–4.13) and 2.60 (95%CI 1.46–4.61), respectively. Genotype frequencies in Japanese AD cases and controls for -111 and -2 SNPs were shown in Table 4.

In further analyses of patient subgroups, we observed strong associations between the presence of high total serum IgE, early age of disease onset ( $\leq 3$ ) and peripheral blood eosinophilia ( $>500/\mu\text{L}$ ), as well as history of childhood asthma and allergic rhinitis (Table 5). No significant differences were observed for the other clinical features tested (data not shown). Notably, the -111T/T genotype was progressively more common in AD with high total serum IgE levels in an IgE-level-dependent manner. Interestingly, when we analyzed



**Figure 1.** (A) A graphical overview of the 36 identified SNPs in relation to the exon/intron structure of the human *IL12RB1* gene. Nucleotide position one (+1) is the first adenine of the initiation codon (ATG) such that SNP positions are given relative to the ATG. The 17 coding exons are shown by black boxes and the 5'- and 3'-UTRs by white blocks. Asterisks indicate SNPs that were genotyped in a larger population. (B) Pair-wise LD, as measured by  $D'$  and  $r^2$ , was calculated for 35 common polymorphisms (MAF  $\geq 10\%$ ) identified in 24 sequenced samples. Two measures of LD are shown:  $D'$  in the lower left triangle and  $r^2$  in the upper right triangle. The markers are plotted equidistantly. Scales for both LD measures are provided below. Asterisks indicate SNPs that were genotyped in a larger population.

the -111A/T SNP in the independent population of physician-diagnosed asthma, the -111T/T genotype frequency in 304 child asthmatics aged 4–15 years (9.2%) tended to be much higher than that in the control group (4.2%). Then, to further confirm the influence of the -111 genotype on IgE regulation, we compared total serum IgE levels in AD patients according to genotype. Although the results for AD patients were not statistically significant, we observed the same trend of

increasing total serum IgE levels with increasing occurrence of the -111T allele (Fig. 2).

### Haplotype analysis

Among eight representative SNPs, SNPs located out of the first LD block were not in strong LD with the -111 and -2 SNPs ( $r^2 \leq 0.6$ ). We analyzed the distribution of